Vaxart Historical Income Statement

VXRT Stock

USD 0.61 0.01 1.67%

Historical analysis of Vaxart income statement accounts such as Depreciation And Amortization of 9.1 M, Interest Expense of 1.4 M, Total Revenue of 7 M or Other Operating Expenses of 75.8 M can show how well Vaxart Inc performed in making a profits. Evaluating Vaxart income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vaxart's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Vaxart Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaxart Inc is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Vaxart Income Statement Analysis

Vaxart Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vaxart shareholders. The income statement also shows Vaxart investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Vaxart Income Statement Chart

At this time, Vaxart's Depreciation And Amortization is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 95.3 M in 2024, despite the fact that Gross Profit is likely to grow to (57.7 M).

Total Revenue Other Operating Expenses Total Operating Expenses Research Development Discontinued Operations

Total Revenue

Total revenue comprises all receipts Vaxart Inc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vaxart Inc. It is also known as Vaxart overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Vaxart's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vaxart Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	70.6M	110.4M	90.7M	95.3M
Cost Of Revenue	48.7M	3.3M	68.1M	53.4M

Total Operating Expenses Cost Of Revenue

Vaxart income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Research Development	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Net Interest Income	Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.3	-0.19	-0.77	0.57	-0.61	-0.64	-0.59	0.62	0.68	-0.6	0.18	-0.61	0.34	0.59	0.65	-0.62	0.08	-0.13	0.61	0.87	0.69	-0.85
Interest Expense	0.3		-0.58	-0.39	-0.08	-0.25	-0.26	-0.25	0.06	0.17	-0.27	0.09	-0.28	0.44	0.16	0.17	-0.2	-0.27	0.37	-0.46	0.15	0.6	-0.11
Total Revenue	-0.19	-0.58		0.51	0.02	0.54	0.53	0.54	0.11	-0.46	0.57	0.0	0.57	-0.19	-0.36	-0.48	0.49	0.69	-0.11	0.25	-0.31	-0.62	0.21
Gross Profit	-0.77	-0.39	0.51		-0.49	0.7	0.72	0.7	-0.69	-0.71	0.73	-0.05	0.73	-0.33	-0.68	-0.73	0.73	0.35	0.14	-0.38	-0.76	-0.79	0.74
Other Operating Expenses	0.57	-0.08	0.02	-0.49		-0.82	-0.83	-0.82	0.45	0.85	-0.79	0.38	-0.79	0.17	0.82	0.81	-0.81	0.23	-0.15	0.63	0.63	0.56	-0.4
Operating Income	-0.61	-0.25	0.54	0.7	-0.82		0.99	0.99	-0.31	-0.98	0.99	-0.27	0.99	-0.27	-0.89	-0.97	0.97	0.2	0.08	-0.41	-0.72	-0.81	0.5
Ebit	-0.64	-0.26	0.53	0.72	-0.83	0.99		1.0	-0.35	-0.98	0.98	-0.35	0.98	-0.27	-0.9	-0.96	0.96	0.16	0.07	-0.43	-0.75	-0.81	0.53
Ebitda	-0.59	-0.25	0.54	0.7	-0.82	0.99	1.0		-0.32	-0.98	0.98	-0.35	0.98	-0.26	-0.9	-0.96	0.95	0.18	0.06	-0.4	-0.71	-0.79	0.49
Cost Of Revenue	0.62	0.06	0.11	-0.69	0.45	-0.31	-0.35	-0.32		0.36	-0.33	0.08	-0.34	0.35	0.32	0.38	-0.38	0.1	-0.12	0.38	0.54	0.4	-0.58
Total Operating Expenses	0.68	0.17	-0.46	-0.71	0.85	-0.98	-0.98	-0.98	0.36		-0.97	0.27	-0.97	0.24	0.86	0.97	-0.96	-0.12	-0.1	0.51	0.79	0.77	-0.6
Income Before Tax	-0.6	-0.27	0.57	0.73	-0.79	0.99	0.98	0.98	-0.33	-0.97		-0.16	1.0	-0.27	-0.85	-0.97	0.98	0.29	0.09	-0.38	-0.74	-0.84	0.52
Total Other Income Expense Net	0.18	0.09	0.0	-0.05	0.38	-0.27	-0.35	-0.35	0.08	0.27	-0.16		-0.16	0.05	0.43	0.19	-0.13	0.44	0.23	0.13	0.08	0.09	0.0
Net Income	-0.61	-0.28	0.57	0.73	-0.79	0.99	0.98	0.98	-0.34	-0.97	1.0	-0.16		-0.3	-0.85	-0.97	0.98	0.28	0.09	-0.37	-0.74	-0.84	0.52
Income Tax Expense	0.34	0.44	-0.19	-0.33	0.17	-0.27	-0.27	-0.26	0.35	0.24	-0.27	0.05	-0.3		0.27	0.23	-0.27	0.13	-0.02	-0.17	0.25	0.36	-0.23
Selling General Administrative	0.59	0.16	-0.36	-0.68	0.82	-0.89	-0.9	-0.9	0.32	0.86	-0.85	0.43	-0.85	0.27		0.85	-0.88	-0.09	-0.19	0.54	0.63	0.67	-0.43
Research Development	0.65	0.17	-0.48	-0.73	0.81	-0.97	-0.96	-0.96	0.38	0.97	-0.97	0.19	-0.97	0.23	0.85		-0.96	-0.28	-0.09	0.52	0.83	0.79	-0.63
Net Income From Continuing Ops	-0.62	-0.2	0.49	0.73	-0.81	0.97	0.96	0.95	-0.38	-0.96	0.98	-0.13	0.98	-0.27	-0.88	-0.96		0.27	0.21	-0.46	-0.73	-0.79	0.52
Non Recurring	0.08	-0.27	0.69	0.35	0.23	0.2	0.16	0.18	0.1	-0.12	0.29	0.44	0.28	0.13	-0.09	-0.28	0.27		-0.03	0.13	-0.18	-0.36	0.12
Non Operating Income Net Other	-0.13	0.37	-0.11	0.14	-0.15	0.08	0.07	0.06	-0.12	-0.1	0.09	0.23	0.09	-0.02	-0.19	-0.09	0.21	-0.03		-0.37	-0.09	0.09	0.09
Net Interest Income	0.61	-0.46	0.25	-0.38	0.63	-0.41	-0.43	-0.4	0.38	0.51	-0.38	0.13	-0.37	-0.17	0.54	0.52	-0.46	0.13	-0.37		0.68	0.19	-0.63
Interest Income	0.87	0.15	-0.31	-0.76	0.63	-0.72	-0.75	-0.71	0.54	0.79	-0.74	0.08	-0.74	0.25	0.63	0.83	-0.73	-0.18	-0.09	0.68		0.73	-0.9
Reconciled Depreciation	0.69	0.6	-0.62	-0.79	0.56	-0.81	-0.81	-0.79	0.4	0.77	-0.84	0.09	-0.84	0.36	0.67	0.79	-0.79	-0.36	0.09	0.19	0.73		-0.49
Selling And Marketing Expenses	-0.85	-0.11	0.21	0.74	-0.4	0.5	0.53	0.49	-0.58	-0.6	0.52	0.0	0.52	-0.23	-0.43	-0.63	0.52	0.12	0.09	-0.63	-0.9	-0.49

Click cells to compare fundamentals

Vaxart Account Relationship Matchups

Vaxart income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	3.6M	1.8M	2.4M	3.3M	8.6M	9.1M
Interest Expense	2.4M	1.9M	1.5M	1.3M	1.4M	1.4M
Total Revenue	9.9M	4.0M	892K	107K	7.4M	7.0M
Gross Profit	(4.7M)	(15.8M)	(47.9M)	(3.2M)	(60.8M)	(57.7M)
Other Operating Expenses	20.7M	35.1M	70.6M	110.4M	90.7M	75.8M
Operating Income	(15.8M)	(30.2M)	(72.8M)	(114.6M)	(83.3M)	(79.2M)
Ebit	(10.7M)	(30.1M)	(68.9M)	(106.4M)	(83.3M)	(79.2M)
Ebitda	(7.1M)	(28.3M)	(66.5M)	(103.1M)	(74.7M)	(71.0M)
Cost Of Revenue	14.5M	19.9M	48.7M	3.3M	68.1M	53.4M
Total Operating Expenses	20.7M	35.1M	70.6M	110.4M	90.7M	95.3M
Income Before Tax	(18.2M)	(32.0M)	(70.4M)	(107.7M)	(82.2M)	(78.1M)
Total Other Income Expense Net	(5.1M)	(1.8M)	2.4M	6.9M	1.1M	1.0M
Net Income	(18.6M)	(32.2M)	(70.5M)	(107.8M)	(82.5M)	(78.3M)
Income Tax Expense	490K	238K	107K	67K	261K	440.2K
Selling General Administrative	6.2M	15.2M	21.9M	29.4M	22.6M	21.2M
Research Development	14.5M	19.9M	48.7M	81.1M	68.1M	71.5M
Net Income From Continuing Ops	(18.6M)	(32.2M)	(70.5M)	(107.8M)	(82.5M)	(78.3M)
Non Operating Income Net Other	(2.2M)	(13K)	(1K)	(6K)	(5.4K)	(5.1K)
Net Income Applicable To Common Shares	(18.6M)	(32.2M)	(70.5M)	(107.8M)	(97.0M)	(92.1M)
Tax Provision	490K	238K	107K	67K	261K	216.2K
Net Interest Income	(2.2M)	(1.8M)	(1.4M)	(58K)	1.2M	1.3M
Interest Income	149K	75K	81K	1.2M	2.7M	2.8M
Reconciled Depreciation	3.6M	2.7M	4.2M	5.8M	8.6M	4.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxart Historical Income Statement

About Vaxart Income Statement Analysis

Vaxart Income Statement Chart

Total Revenue

Other Operating Expenses

Total Operating Expenses

Vaxart income statement Correlations

Vaxart Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vaxart income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Vaxart Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Ebit	+ 0.99	Operating Income
Ebitda	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Operating Income
Net Income	+ 0.99	Operating Income

Total Operating Expenses	- 0.98	Ebitda
Total Operating Expenses	- 0.98	Ebit
Total Operating Expenses	- 0.98	Operating Income
Research Development	- 0.97	Net Income
Research Development	- 0.97	Income Before Tax
Net Income	- 0.97	Total Operating Expenses